AstraZeneca’s Brilinta Fails to Beat Older Medicine in Trial
- Euclid trial result is latest blow to sales ambitions
- U.K. drugmaker had projected $3.5 billion in 2023 revenue
This article is for subscribers only.
AstraZeneca Plc’s heart medicine Brilinta didn’t beat a generic blood-thinner in patients with peripheral artery disease, the latest blow to the drugmaker’s ambitions for the treatment after it failed a test in March.
Brilinta was pitted against clopidogrel in a trial of almost 14,000 people in 28 countries, the largest test of its kind in patients with symptoms of the disease. The trial, dubbed Euclid, is part of a larger program that studies the effects of the drug in patients with peripheral artery disease and diabetes. The full results of the trial will be presented at the American Heart Association Scientific Sessions in New Orleans next month, the U.K. drugmaker said in a statement Tuesday.